Join us for a KOL Event with Mendus, featuring Amer Zeidan, MBBS, MHS (Yale School of Medicine) and Uwe Platzbecker, MD (University Hospital in Leipzig) who will discuss the current treatment landscape in acute myeloid leukemia (AML), and the emergence of maintenance therapy as a new paradigm for treatment of AML patients in remission.

The discussion will set the stage for the upcoming data that will be presented in an oral presentation at the American Society of Hematology Annual Meeting on December 12, 2022 from the ongoing Phase 2 ADVANCE II study evaluating DCP-001 as a potential maintenance therapy for AML patients in remission with measurable residual disease (MRD). The results will include survival data for the first time, as well as updates from the previously reported MRD conversion rate and immunological responses.

A live Q&A session will follow the formal presentations.